Our results demonstrate that dipeptide species support CML stem cell maintenance by activating p38MAPK–Smad3 signalling in vivo, and thus point towards a potential therapeutic target for CML treatment. This evidence concerns the gene SMAD3 and chronic myelogenous leukemia, BCR-ABL1 positive.